GreenLight Biosciences Holdings (GRNA)
Market Cap | 70.34M |
Revenue (ttm) | 6.78M |
Net Income (ttm) | -167.06M |
Shares Out | 151.55M |
EPS (ttm) | -1.27 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 417,054 |
Open | 0.443 |
Previous Close | 0.448 |
Day's Range | 0.421 - 0.470 |
52-Week Range | 0.317 - 11.340 |
Beta | 1.48 |
Analysts | Buy |
Price Target | 4.85 (+945.03%) |
Earnings Date | Mar 28, 2023 |
About GRNA
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts. [Read more]
Financial Performance
In 2022, GRNA's revenue was $6.78 million, an increase of 325.08% compared to the previous year's $1.60 million. Losses were -$167.06 million, 48.7% more than in 2021.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for GRNA stock is "Buy." The 12-month stock price forecast is $4.85, which is an increase of 945.03% from the latest price.
News

GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results
BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world's toughest ...

GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D Day
-- Progressing human health pipeline conferring mRNA platform advantages for infectious disease and personalized oncology medicines; pursuing capital efficient strategy targeting unmet medical needs, ...

GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D Day
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world's toughest ...

GreenLight Biosciences to Host R&D Day Series on Plant and Human Health Development Strategy
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world's toughest ...

GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate
KIGALI, Rwanda and Lexington, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address s...

GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines
BOSTON and PROVIDENCE, R.I., Jan. 09, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (Nasdaq:GRNA), and EpiVax Therapeutics Inc, today announced that they have signed an exclusive colla...

GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (Nasdaq:GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and afforda...

GreenLight Biosciences to Participate in Upcoming Investor Conferences in November
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the potential of RNA to address some of the world's toughest proble...

GreenLight Biosciences to cut 25% of its workforce as part of ‘realignment' to extend cash runway
GreenLight Biosciences Holdings GRNA, -1.44% said Wednesday that it was laying off 25% of its workforce as part of a “realignment” aimed at saving cash as it shifts its focus to near-term value driver...

GreenLight Biosciences announces realignment to focus on near-term value drivers
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for every...

GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA
BOSTON and BRISBANE, Australia, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Researchers from Boston's GreenLight Biosciences and the Queensland University of Technology (QUT) in Brisbane, Australia, have annou...

Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More
The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.

GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for every...

GreenLight Biosciences announces $109 million financing
BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for every...

GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine
GreenLight's messenger RNA production process is transferable to large-scale equipment and CMO facilities Technology transfer and scale-up from lab bench to Samsung's commercial facility was completed...

NIH, GreenLight Biosciences to collaborate on COVID-19 vaccine development for new variants
BOSTON, July 29, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences has announced a collaboration with the National Institutes of Health (NIH) to develop COVID-19 vaccines that are more broadly protectiv...

GreenLight's honeybee-saving RNA solution named finalist in World Changing Ideas Award
BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- An RNA-based solution by GreenLight Biosciences designed to protect honeybees from the Varroa destructor mite was named a finalist by Fast Company for its 2022...

Co-developer of COVID-19 Vaccine Joins GreenLight Advisory Board
BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC, a biotechnology company focused on RNA research, product design, development, and manufacturing for human, animal, and plant hea...

GreenLight Biosciences Holdings, PBC (GRNA) enters into multitarget licensing agreement with Serum Institute of India to develop and commercialize messenger RNA products for emerging markets globally
BOSTON and PUNE, India, March 14, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings PBC today announced a licensing agreement with Serum Institute of India, Pvt, Ltd., aimed at accelerating acc...

Environmental Impact Acquisition Corporation approval obtained; GreenLight Biosciences set to begin trading under Nasdaq: GRNA on February 3, 2022
BOSTON, Feb. 2, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation (NASDAQ: ENVI), a publicly-traded special purpose acquisition company, announced today that its business combination w...

GreenLight Biosciences and Germains Seed Technology Partner to Explore Development of World's First dsRNA Seed Treatment to Control Pests
BOSTON, Jan. 31, 2022 /PRNewswire/ -- GreenLight Biosciences and Germains Seed Technology, an industry leader in seed treatment technologies, today announced a research partnership agreement that coul...

ENVI Announces Quorum to Pass Business Combination With GreenLight Biosciences and Achievement of All Transaction Requirements Following the Redemption Deadline
BOSTON, Jan. 28, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation ("ENVI" or the "Company") (Nasdaq: ENVI) today announced that it had achieved a quorum for the special meeting of its...

ENVI and GreenLight Biosciences Announce Filing of Definitive Proxy Statement/Prospectus and the February 1st, 2022 Special Meeting to Approve Proposed Business Combination
BOSTON, Jan. 14, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation (NASDAQ: ENVI) ("ENVI"), a publicly-traded special purpose acquisition company, announced today that ENVI's definitiv...

GreenLight Biosciences (ENVI) partners with IAVI to accelerate COVID-19 vaccine trial in Africa
NEW YORK, Nov. 30, 2021 /PRNewswire/ -- GreenLight Biosciences has partnered with the non-profit scientific research organization IAVI to work together on a Phase I clinical trial in Africa. IAVI and ...

GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing
BOSTON and INCHEON, South Korea, Nov. 24, 2021 /PRNewswire/ -- GreenLight Biosciences (Nasdaq: ENVI), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessi...